No Data
No Data
Zhixiang Jintai (688443): Celizumab approved soon, multiple assets are in the advanced clinical phase
The 2023 results are in line with our expectations. The company announced its 2023 results: net profit to mother - 801 million yuan, mainly due to multiple innovative drug assets to advance the post-clinical phase. Expenses are high, and the company's 23-year performance is in line with our expectations.
Zhixiang Jintai (688443): GR1501 is about to be approved, and the pipeline has sufficient reserve capacity
Guide to this report: The company released its 2023 and 2024 quarterly reports. The performance was in line with expectations, R&D investment was further increased, and clinical practice progressed steadily. GR1501 submitted supplementary materials on 24.2, and is expected to be in 2024
Zhixiang Jintai (688443.SH) reported first-quarter results with a net loss of 164 million yuan
Zhixiang Jintai (688443.SH) released its report for the first quarter of 2024, with revenue of 6,330.27...
Open Source Securities released a research report on April 17 stating that it gave Zhixiang Jintai (688443.SH) a purchase rating. The main reasons for the rating include: 1) Zhixiang Jintai: focusing on antibody drug technology research and development, d
Open Source Securities released a research report on April 17 stating that it gave Zhixiang Jintai (688443.SH) a purchase rating. The main reasons for the rating include: 1) Zhixiang Jintai: focusing on antibody drug technology research and development, deepening the three major fields of self-immunity, anti-infection and cancer; 2) Celizumab: the target scoquiumab, which is expected to become the earliest domestically produced IL-17A monoclonal antibody to be marketed; 3) the core pipeline GR1802 and GR1801 are progressing ahead and have great potential for growth. (Mainichi Keizai Shimbun)
Zhixiang Jintai (688443) Company's first coverage report: Focusing on antibody drug development, the single product IL-17A monoclonal antibody is expected to be approved soon
Zhixiang Jintai: Focusing on antibody drug technology research and development, Zhixiang Jintai is an innovative biopharmaceutical company driven by antibody drug discovery technology in the three major fields of self-prevention, anti-infection, and cancer diseases. The company focuses on the fields of self-prevention, anti-infection, and oncology, and has
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
No Data